Ganetespib: Research and clinical development

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1849-1858

  Jhaveri, Komal ^a   Modi, Shanu ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Colorectal cancer; HSP90; Lung cancer

Indexed keywords

AFLIBERCEPT; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; DOXORUBICIN; FULVESTRANT; GANETESPIB; HEAT SHOCK PROTEIN 90; PACLITAXEL; PEMETREXED; RAPAMYCIN; TRASTUZUMAB;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EVALUATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; FATIGUE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; LUNG ADENOCARCINOMA; LUNG CANCER; MANTLE CELL LYMPHOMA; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RECTUM CANCER; REVIEW; SARCOMA; SMALL CELL LUNG CANCER; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; UTERINE TUBE TUMOR;

EID: 84938125248     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S65804     Document Type: Review

References (61)

1. Clare DK, Saibil HR. ATP-driven molecular chaperone machines. Biopolymers. 2013;99(11):846-859.
2. Lai BT, Chin NW, Stanek AE, Keh W, Lanks KW. Quantitation and intracellular localization of the 85 K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol. 1984;4(12):2802-2810.
3. Taldone T, Patel HJ, Bolaender A, Patel MR, Chiosis G. Protein chaperones: a composition of matter review (2008-2013). Expert Opin Ther Pat. 2014;24(5):501-518.
4. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem. 2009;17(6):2225-2235.
5. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761-772.
6. Nanbu K, Konishi I, Mandai M, et al. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev. 1998;22(6):549-555.
7. Uozaki H, Ishida T, Kakiuchi C, et al. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract. 2000;196(10):665-673.
8. Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol. 2006;1(5):279-284.
9. Moulick K, Ahn JH, Zong H, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 2011;7(11):818-826.
10. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14(9):e358-e369.
11. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl). 2004;82(8):488-499.
12. Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol. 2012;65:471-517.
13. Richter K, Buchner J. Hsp90: chaperoning signal transduction. J Cell Physiol. 2001;188(3):281-290.
14. Pearl LH, Prodromou C. Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem. 2001;59:157-186.
15. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2002;2(1):3-24.
16. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18(1):64-76.
17. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem. 1996;271(37):22796-22801.
18. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010;53(1):3-17.
19. Ali MM, Roe SM, Vaughan CK, et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature. 2006;440(7087):1013-1017.
20. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets. 2003;3(5):301-323.
21. Ehrlich ES, Wang T, Luo K, et al. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci U S A. 2009;106(48):20330-20335.
22. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823(3):742-755.
23. Jhaveri K, Ochiana SO, Dunphy MP, et al. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs. 2014;23(5):611-628.
24. Jhaveri K, Miller K, Rosen L, et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res. 2012;18(18):5090-5098.
25. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010;28(33):4953-4960.
26. Wagner AJ, Chugh R, Rosen LS, et al. A phase 1 study of the heat shock protein 90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft tissue sarcomas. Clin Cancer Res. 2013;19(21):6020-6029.
27. Modi S, Saura C, Henderson C, et al. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2013;139(1):107-113.
28. Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012;11(2):475-484.
29. Proia DA, Foley KP, Korbut T, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 2011;6(4):e18552.
30. Shimamura T, Perera SA, Foley KP, et al. Ganetespib (STA-9090), a non-geldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012;18(18):4973-4985.
31. Zhou D, Liu Y, Ye J, et al. A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats. Mol Cancer Ther. 2011;10(11 suppl):Abstr C212.
32. Jhaveri K, Chandarlapaty S, Lake D, et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 2014;14(3):154-160.
33. Goldman JW, Raju RN, Gordon GA, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013;13:152.
34. Cho DC, Heath EI, Cleary JM, et al. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report. General Poster Session, Developmental Therapeutics - Experimental Therapeutics, 2011 ASCO Annual Meeting, Abstract 3051; 2011. Chicago.
35. Lancet JE, Smith BD, Bradley R, Komrokji RS, Teofilovici F, Rizzieri DA. A phase 1/2 study of the potent Hsp90 inhibitor STA-9090 administered once weekly in subjects with hematologic malignancies. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 3294.
36. Padmanabhan S, Kelly K, Heaney M, et al. A phase I study of the potent Hsp90 inhibitor STA-9090 administered twice weekly in subjects with hematologic malignancies. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 2898.
37. Proia DA, Zhang C, Sequeira M, et al. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Clin Cancer Res. 2014;20(2):413-424.
38. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
39. Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013;19(11):3068-3077.
40. Demetri GD, Heinrich MC, Chmielowski B, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. ASCO Annual Meeting, 2011 (Vol 29, No 15_suppl (May 20 Supplement); 2011. Chicago.
41. Nguyen DM, Lorang D, Chen GA, Stewart JH 4th, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg. 2001;72(2):371-378; discussion 378-379.
42. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin Cancer Res. 7:2155-2158, 2001. Clin Cancer Res. 2001;7(8):2228-2236.
43. Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res. 2014;74(5):1294-1300.
44. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003;63(9):2139-2144.
45. Proia DA, Sang J, He S, et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. 2012;30(6):2201-2209.
46. Liu H, Xiao F, Serebriiskii IG, et al. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res. 2013;19(18):5053-5067.
47. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62(23):6997-7000.
48. Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn. 2008;10(6):493-495.
49. Acquaviva J, Smith DL, Sang J, et al. Targeting KRAS mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther. 2012;25:2012.
50. Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013;3(4):430-443.
51. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535-7540.
52. Acquaviva J, Smith DL, Jimenez JP, et al. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther. 2014;13(2):353-363.
53. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 2010;126(5):1216-1225.
54. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res. 2003;9(10 pt 1):3749-3755.
55. Scaltriti M, Dawood S, Cortes J. Molecular pathways: targeting hsp90 - who benefits and who does not. Clin Cancer Res. 2012;18(17):4508-4513.
56. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99(22):14374-14379.
57. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006;107(3):1092-1100.
58. Richardson PG, Badros AZ, Jagannath S, et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010;150(4):428-437.
59. Richardson PG, Chanan-Khan AA, Lonial S, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011;153(6):729-740.
60. Ramalingam S, Goss G, Rosell R, et al. A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). J Clin Oncol. 2013;31(suppl):abstr CRA8007.
61. Jhaveri K, Chandarlapaty S, Lake D, et al. A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer. Abstract # 1403. Presented at the San Antonio Breast Cancer Symposium, December 2014; 2014. San Antonio.